{"product_id":"edgewisetx-five-forces-analysis","title":"Edgewise Therapeutics Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEdgewise Therapeutics faces moderate buyer power, high regulatory barriers, and intense substitute threats from established neuromuscular and neuropathic pain treatments, while supplier leverage and rivalry among biotech peers shape its strategic posture.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Edgewise Therapeutics’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Contract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise Therapeutics depends on specialized contract manufacturing organizations (CMOs) for complex small molecules like sevasemten; as of late 2025 only about 30–40 global facilities meet stringent GMP standards for orphan drugs, giving CMOs strong leverage to demand premium pricing and priority slotting—industry surveys show CMO day rates up ~18% since 2022—so supply constraints can delay timelines and raise COGS significantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Skilled Scientific Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe biotech sector has a persistent shortage of specialists for rare muscle diseases like Duchenne (DMD) and Becker (BMD); NIH data shows ~40% of rare-disease clinical roles remain hard-to-fill in 2024, boosting supplier power.\u003c\/p\u003e\n\u003cp\u003eThese experts hold outsized leverage because their know-how is critical for complex trials and FDA\/EMA filings; losing one lead clinician can delay programs by 6–12 months.\u003c\/p\u003e\n\u003cp\u003eEdgewise must offer competitive pay and equity—market median total comp for senior rare-disease scientists was $280k–$420k in 2025—to retain talent through 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organization Dependency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConducting global rare-disease trials needs specialized Clinical Research Organizations (CROs) that supply site networks, patient registries, and regulatory-grade data systems; in 2024 top CROs captured ~46% of biotech outsourced R\u0026amp;D spend, concentrating power.\u003c\/p\u003e\n\u003cp\u003eCROs control trial logistics and data management critical for FDA and EMA milestones, and median cost to replace a CRO mid-study exceeds $5–10M plus 6–12 months delay, so switching is rarely viable.\u003c\/p\u003e\n\u003cp\u003eThis lock-in gives CROs high bargaining power over Edgewise Therapeutics, raising contract pricing and milestone-risk exposure during its clinical-stage programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Research Equipment and Reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProprietary lab instruments and ultra-pure reagents are critical for Edgewise Therapeutics’ oral small-molecule programs; top suppliers like Thermo Fisher Scientific and Merck hold patents and exclusive lines that limit substitution.\u003c\/p\u003e\n\u003cp\u003eIn 2025, specialized reagent lead times averaged 12–20 weeks and single-vendor dependency raised R\u0026amp;D delay risk; a supply interruption could push 2026 milestones by quarters and raise costs by an estimated 8–15%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh supplier concentration: few patent holders\u003c\/li\u003e\n\u003cli\u003eLead times 12–20 weeks (2025 data)\u003c\/li\u003e\n\u003cli\u003ePotential 8–15% R\u0026amp;D cost increase if disrupted\u003c\/li\u003e\n\u003cli\u003eDelays could shift 2026 timelines by multiple quarters\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Licensing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdgewise often licenses foundational chemistries from universities or biotechs; these licensors set royalty rates and milestone structures that can take 5–15% of net sales and $1m–$50m in development milestones, directly squeezing long‑term margins as Edgewise nears commercialization in rare diseases.\u003c\/p\u003e\n\u003cp\u003eKeeping strong IP partnerships is critical: renegotiation risks, exclusivity terms, and sublicense rights affect launch timing, valuation, and investor returns—royalties can lower peak free cash flow by millions annually.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTypical royalty range: 5–15% of net sales\u003c\/li\u003e\n\u003cli\u003eCommon milestones: $1m–$50m per program\u003c\/li\u003e\n\u003cli\u003eImpact: reduces peak FCF and valuation multiples\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier squeeze: limited GMP CMOs, rising rates, long lead times, high CRO costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high bargaining power: few GMP CMOs (30–40 global), CMO day rates +18% since 2022, reagent lead times 12–20 weeks, CROs captured ~46% of outsourced R\u0026amp;D spend (2024), replacing a CRO costs $5–10M +6–12 months, typical royalties 5–15% of net sales, potential R\u0026amp;D cost uplift 8–15% if disrupted.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25 Data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP CMOs\u003c\/td\u003e\n\u003ctd\u003e30–40\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO rate change\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent lead time\u003c\/td\u003e\n\u003ctd\u003e12–20 wks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO market share\u003c\/td\u003e\n\u003ctd\u003e46%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO switch cost\u003c\/td\u003e\n\u003ctd\u003e$5–10M,+6–12m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e5–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D cost risk\u003c\/td\u003e\n\u003ctd\u003e+8–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Edgewise Therapeutics, this Porter's Five Forces overview uncovers competitive drivers, customer and supplier power, entry barriers, substitutes, and emerging threats shaping its market position and strategic options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for Edgewise Therapeutics—ideal for rapid strategic decisions and slide-ready use in meetings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Third Party Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpin the us and eu a handful of insurers national health systems buy most high-cost orphan drugs giving them outsized leverage over edgewise therapeutics. these payers demand steep rebates or flat-out deny coverage unless therapies demonstrate clear cost-effectiveness often using icer-style thresholds per qaly in debates by end-2025 heightened pricing scrutiny including medicare negotiation expansion hta coordination has strengthened ability to extract deeper discounts limit formularies pressuring launch strategies.\u003e\n\u003c\/pin\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Reimbursement Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment programs like Medicare and Medicaid act as pivotal customers, setting benchmark prices and reimbursement that influence private payers; Medicare Part B\/Part D and Medicaid account for roughly 40% of US prescription spending as of 2024. Recent legislation through 2024–2025 introduced Medicare drug price negotiations for top-spend drugs and inflation rebates, which could cap Edgewise Therapeutics’ revenue for high-cost therapies. If Edgewise fails to secure favorable reimbursement codes or add-on payments, patient access and market penetration may be sharply limited, cutting potential peak sales by an estimated 20–40% in modeled scenarios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Patient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cppatient advocacy groups for duchenne and becker muscular dystrophy foundation parent project shape demand reimbursement: a survey found of families report endorsements influenced treatment choices advocacy-backed therapies saw faster payer coverage. although not payers their sway regulators insurers pressuring reimbursement decisions formulary placement. edgewise must invest in ongoing liaison transparent data sharing patient-centered outcomes to secure backing drive uptake.\u003e\n\u003c\/ppatient\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Benefit Manager Formulary Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePharmacy Benefit Managers (PBMs) decide which drugs sit on preferred formularies for ~200 million insured US lives, so excluding sevasemten or placing it in a high-cost tier could cut Edgewise’s addressable market dramatically.\u003c\/p\u003e\n\u003cp\u003eSecuring preferred placement is critical as sevasemten nears launch; PBM-negotiated rebates often exceed 20–40% for specialty drugs, directly reducing net price and revenue.\u003c\/p\u003e\n\u003cp\u003eWithout formulary access, commercial uptake, prescribing rates, and peak sales forecasts (tens to hundreds of millions annually) would be materially impaired.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePBMs control formulary access for ~200M US lives\u003c\/li\u003e\n\u003cli\u003eTypical specialty rebates: 20–40%\u003c\/li\u003e\n\u003cli\u003eFormulary exclusion = major hit to peak sales\u003c\/li\u003e\n\u003cli\u003eFavorable placement required for sevasemten launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Orphan Disease Patient Pool\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLimited patient pools for Duchenne (DMD) and Becker (BMD)—prevalence ~1 in 3,600–6,000 male births for DMD and lower for BMD—mean losing a few percent of patients to competitors can cut revenue sharply; a 5% share shift in a 10,000-patient addressable market equals 500 patients and large revenue swings for Edgewise.\u003c\/p\u003e\n\u003cp\u003eScarcity increases collective buyer power: payers, advocacy groups, and centers of excellence can steer treatment choice, so Edgewise must show superior safety and efficacy in trials and real-world data to win and keep this concentrated cohort.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAddressable market ~8,000–12,000 patients (US+EU).\u003c\/li\u003e\n\u003cli\u003e5% loss ≈ 400–600 patients—material revenue impact.\u003c\/li\u003e\n\u003cli\u003eDecisions influenced by centers of excellence and payers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers squeeze Edgewise: 20–40%+ rebates, $100–150k\/QALY caps threaten 400–600 patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cppayers medicare pbms hold strong leverage over edgewise demanding rebates and using cost-effectiveness thresholds to limit coverage negotiation expansion eu hta coordination tighten pricing. small duchenne pools us magnify impact: losing patients. advocacy groups centers of excellence sway formulary access uptake.\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRebates (specialty)\u003c\/td\u003e\n\u003ctd\u003e20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICER thresholds\u003c\/td\u003e\n\u003ctd\u003e$100–150k\/QALY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAddressable patients\u003c\/td\u003e\n\u003ctd\u003e8,000–12,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5% share shift\u003c\/td\u003e\n\u003ctd\u003e400–600 patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/ppayers\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eEdgewise Therapeutics Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Edgewise Therapeutics Porter’s Five Forces analysis you’ll receive immediately after purchase—no mockups or placeholders; the final, fully formatted document is ready for instant download and use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746920608121,"sku":"edgewisetx-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/edgewisetx-five-forces-analysis.png?v=1772193286","url":"https:\/\/matrixbcg.com\/products\/edgewisetx-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}